American Journal of Preventive Medicine
Volume 38, Issue 1 , Pages 47-53 , January 2010

Use of Antithrombotic Agents Among U.S. Stroke Survivors, 2000–2006

  • Eric M. Cheng, MD, MS

      Affiliations

    • Department of Neurology, Health Services Research Program, David Geffen School of Medicine, University of California, Los Angeles, California
    • Department of Neurology, VA Greater Los Angeles Healthcare System, Los Angeles, California
    • HSR&D Center of Excellence, VA Greater Los Angeles Healthcare System, Sepulveda, California
    • Corresponding Author InformationAddress correspondence and reprint requests to: Eric M. Cheng, MD, MS, VA Greater Los Angeles Healthcare System, Department of Neurology, 11301 Wilshire Boulevard, Building 500, ML 127, Los Angeles CA 90073
    • ,
  • Stanley N. Cohen, MD

      Affiliations

    • Stroke Prevention Program, Nevada Neurosciences Institute at Sunrise, Las Vegas, Nevada
    • ,
  • Martin L. Lee, PhD

      Affiliations

    • Department of Biostatistics, UCLA School of Public Health, Los Angeles, California
    • HSR&D Center of Excellence, VA Greater Los Angeles Healthcare System, Sepulveda, California
    • ,
  • Stefanie D. Vassar, MS

      Affiliations

    • Department of Neurology, Health Services Research Program, David Geffen School of Medicine, University of California, Los Angeles, California
    • Department of Neurology, VA Greater Los Angeles Healthcare System, Los Angeles, California
    • ,
  • Alex Y. Chen, MD, MS

      Affiliations

    • Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California

References 

  1. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998;114(5S):S683–S698
  2. Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 1999;30(9):1991–1994
  3. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke. 1999;30(11):2502–2511
  4. Shahar E, Folsom AR, Romm FJ, et al. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1996;131(5):915–922
  5. O'Connor PJ, Pronk NP, Tan AW, Rush WA, Gray RJ. Does professional advice influence aspirin use to prevent heart disease in an HMO population?. Eff Clin Pract. 1998;1(1):26–32
  6. Cook NR, Chae C, Mueller FB, Landis S, Saks AM, Hennekens CH. Mis-medication and underutilization of aspirin in the prevention and treatment of cardiovascular disease. Med Gen Med. 1999;E1
  7. Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24(2):197–201
  8. Brown JB, Delea TE, Nichols GA, Edelsberg J, Elmer PJ, Oster G. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med. 2002;162(2):193–199
  9. Kim C, Beckles GL. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med. 2004;27(1):1–7
  10. Persell SD, Baker DW. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med. 2004;164(22):2492–2499
  11. Brown DW, Shepard D, Giles WH, Greenlund KJ, Croft JB. Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. Ethn Dis. 2005;15(4):620–626
  12. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in U.S. ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2(12):e353
  13. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30(1):74–77
  14. Opotowsky AR, McWilliams JM, Cannon CP. Gender differences in aspirin use among adults with coronary heart disease in the U.S. J Gen Intern Med. 2007;22(1):55–61
  15. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the U.S.: results of a national survey. Am J Prev Med. 2007;32(5):403–407
  16. Diener PH-C, Bogousslavsky PJ, Brass PLM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–337
  17. Cheng E, Chen A, Vassar S, Lee M, Cohen S, Vickrey B. Comparison of secondary prevention care after myocardial infarction and stroke. Cerebrovasc Dis. 2006;21:235–241
  18. Cohen SB. Design strategies and innovations in the Medical Expenditure Panel Survey. Med Care. 2003;41(7S):III5–III12
  19. Cairns JA, Theroux P, Lewis HD, Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest. 1998;114(5S):S611–S633
  20. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104(13):1577–1579
  21. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146
  22. Muntner P, DeSalvo KB, Wildman RP, Raggi P, He J, Whelton PK. Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiol. 2006;163(10):913–920
  23. Commitee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339
  24. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13
  25. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get with the guidelines–stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119:107–115
  26. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28(9):1411–1424
  27. Glader E-L, Stegmayr B, Norrving B, et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke. 2003;34(8):1970–1975
  28. Tuhrim S, Cooperman A, Rojas M, et al. The association of race and sex with the underuse of stroke prevention measures. J Stroke Cerebrovasc Dis. 2008;17(4):226–234
  29. Simpson CR, Wilson C, Hannaford PC, Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke. 2005;36(8):1771–1775
  30. Walker MK, Whincup PH, Shaper AG, Lennon LT, Thomson AG. Validation of patient recall of doctor-diagnosed heart attack and stroke: a postal questionnaire and record review comparison. Am J Epidemiol. 1998;148(4):355–361
  31. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;57(10):1096–1103

PII: S0749-3797(09)00633-3

doi: 10.1016/j.amepre.2009.08.029

American Journal of Preventive Medicine
Volume 38, Issue 1 , Pages 47-53 , January 2010

Article Tools